Navigation Links
Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
Date:10/1/2007

CEO Glenn A. Oclassen to Join Sleep Experts in Panel Hosted by Natixis

Bleichroeder

PT. RICHMOND, Calif., Oct. 1 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, President and Chief Executive Officer, will participate in a panel focused on middle-of-the-night (MOTN) insomnia at the Natixis Bleichroeder "Hidden Gems" Healthcare Conference.

Date: Monday, October 8, 2007

Panel Discussion: 3:45 p.m. ET

Company Presentation: 4:45 p.m. ET

Location: The Carlton Hotel at 88 Madison Avenue, New York, NY

Mr. Oclassen commented, "This is the first panel sponsored by the investment community to discuss the form of insomnia that is characterized by patients who awaken in the middle of the night and have difficulty returning to sleep. According to a recent survey conducted by the Stanford Sleep Epidemiology Research Center, it is estimated that up to 35% of Americans over the age of 18 suffer primarily from this and related forms of sleep disorder. Despite this large patient population, there is no pharmaceutical agent currently approved to treat this common sleep problem."

"Transcept is developing Intermezzo(TM) (zolpidem tartrate lozenge) for the treatment of such MOTN insomnia. In a recently completed Phase 3 sleep laboratory study, Intermezzo(TM) met the primary endpoint of decreasing sleep onset after a middle of the night awakening, without next day residual effects. I look forward to participating in this panel with these respected sleep experts and raising awareness of this aspect of insomnia."

The MOTN insomnia panel will be co-hosted by Corey Davis, Ph.D., and Jon LeCroy, M.D. of Natixis Bleichroeder. The panel of sleep experts will include Martin B. Scharf, PhD, Director, Center for Research in Sleep Disorders, Cincinnati, Ohio and Gary K. Zammit, Ph.D., Director of the Sleep Disorders Institute at St. Luke's/Roosevelt Hospital, NYC.

<
'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Bruker Participates in Dutch Funded Super Microscope Project
4. Venture Investors early-stage fund grows to $115 million
5. Investor warns of angel-venture funding gap
6. Brazilian bio-industry should impress American investors
7. Investors raise $25 million for biodiesel plant
8. Bio-energy and cleantech grab attention of investors
9. Venture Investors to open Michigan office
10. Early-stage executives hear from investors
11. Commerce qualifies seven for investor tax credits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... (PRWEB) August 19, 2014 2014 ... Industry” is a professional and in-depth research report ... basic Linalool information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:8/18/2014)... --  Sterne, Kessler, Goldstein & Fox P.L.L.C. , an ... , announced today that it has filed eleven ... the U.S. Patent and Trademark Office (USPTO) on behalf ... (Nasdaq: BRLI).  These IPR petitions aim to nullify eleven ... These patents have been asserted against GeneDx in patent ...
(Date:8/18/2014)... August 18, 2014 According ... Market, By Application (Municipal Wastewater Treatment and Industrial ... and Multi Tubular), By Configuration (Internal/Submerged and External/Sidestream), ... by MarketsandMarkets, The market for membrane bioreactor systems ... growing at a CAGR of 15.28% between 2014 ...
(Date:8/18/2014)... , 18. August 2014 Vier ... eine internationale klinische Studie auf, in der ... Linse soll das Sehvermögen bei allen Entfernungen ... Operation möglicherweise keine Lese- oder Gleitsichtbrille mehr ... Namen FluidVision Accommodating Intraocular Lens ...
Breaking Biology Technology:Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... PharmAthene, Inc.,(Amex: PIP ), a biodefense ... threats, announced today that the Company,will present ... on its,Protexia(R) and Valortim(R) medical countermeasures programs ... Countermeasures Enterprise,(PHEMCE) Stakeholders Workshop 2008 / BARDA ...
... Equity, LLC issues a Q4/08,review of Neurobiological ... Outcome Scenarios, Probabilities Appear Focused to the ... at our website:, http://www.scimitarequity.com , Neurobiological ... in the business of acquiring and developing ...
... New Sales Agent and Distributor Gains Quick Traction in ... (BIEL) announced today that the new sales agent it ... for,approximately $400,000 in new sales in the Middle Eastern ... has hit the ground running and is,finding wide marketing ...
Cached Biology Technology:PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008 2Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC 2BioElectronics Corp. Announces $400,000 in New Orders From the Middle East 2
(Date:8/18/2014)... 2014 ,Trustonic TEE ... smart devices  Trustonic, the leading provider ... and Fingerprint Cards AB (FPC) today announced a ... secure biometric authentication on connected devices. ... (FPC1020, FPC1021 and FPC1150) and sensor driver software ...
(Date:8/18/2014)... to a major Arizona watershed may lose access to ... water flow is reduced by the effects of climate ... species, found in the Verde River Basin, are already ... to various resources throughout the river and its tributary ... roundtail chub (Gila robusta) and Sonora sucker (Catostomus insignis). ...
(Date:8/18/2014)... the University of Wisconsin-Madison, USA, have developed a new approach ... and land use change. This new metric was used to ... rates of climate and land use for the US from ... been published in Nature Climate Change , highlight areas ... ecosystem function due to the individual or combined effects of ...
Breaking Biology News(10 mins):Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 2Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 3Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 4Climate change will threaten fish by drying out Southwest US streams, study predicts 2Climate change will threaten fish by drying out Southwest US streams, study predicts 3The double threat of climate and land use change enhances risks to biodiversity 2
... light on the causes of Parkinson,s disease, researchers report that ... mitochondria. A shutdown in fuel can have devastating effects on ... energy despite making up only 2 percent of body weight. ... FDA approved drugs early on may prevent or delay the ...
... CAMBRIDGE, Mass. -- By creating a better way to ... with MIT,s Picower Institute for Learning and Memory and the ... synapse formation. These studies could also help further understanding of ... and Fragile X syndrome. The study will appear in the ...
... their dosages may be standardized, but not every patient ... personal genetic characteristics of individuals and populations can explain ... not another, so medical researchers are adopting the new ... lab is leading the way. Dr. Noam ...
Cached Biology News:In Parkinson's disease, brain cells abandon mitochondria, researchers report 2In Parkinson's disease, brain cells abandon mitochondria, researchers report 3MIT researchers develop a better way to see molecules at work in living brain cells 2An X-ray for your genes 2
... The Genome Sequencer 20 System revolutionizes DNA ... parallel fashion. The Genome Sequencer 20 ... Reagents and consumables for library construction, ... mapping and de novo assembly ...
... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
... demonstrated that oxidative stress is involved in ... stress is the condition in which an ... exist leading to the damage of a ... stress is through several antioxidant systems4 that ...
Biology Products: